Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Dynamin pleckstrin homology (PH) domain is a specialized protein module within the dynamin GTPase family, primarily responsible for targeting the enzyme to the plasma membrane by binding to phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) (UniProt: Q05193). This interaction is essential for the recruitment of dynamin to the necks of budding vesicles, where it oligomerizes to facilitate membrane scission during clathrin-mediated endocytosis (PubMed: 10652310). Beyond its role in vesicle trafficking, the PH domain also interacts with the actin cytoskeleton and various signaling proteins, making it a central hub for cellular remodeling. In clinical contexts, mutations in the PH domain of Dynamin-2 are linked to neuromuscular disorders such as Charcot-Marie-Tooth disease and centronuclear myopathy (PubMed: 16227997). Furthermore, because dynamin is often hijacked by viruses for cellular entry and is overexpressed in several cancers, the PH domain has emerged as a viable therapeutic target. Small molecule inhibitors like MiTMAB and Dyngo-4a specifically target this domain to disrupt lipid binding, offering a strategy to block endocytosis-dependent processes in disease (PubMed: 21524197). However, the high conservation of PH domains across different proteins poses a challenge for achieving high drug specificity and minimizing off-target effects.
Inhibition of the interaction between the pleckstrin homology domain and membrane phosphoinositides, specifically phosphatidylinositol 4,5-bisphosphate (PIP2), which prevents the recruitment of dynamin to the plasma membrane and inhibits vesicle scission.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynamin pleckstrin homology domain (Dynamin PH domain).